Key Points
- Director S. Louise Phanstiel completed multiple open‑market buys totaling ~104,507 shares across Feb. 25–27 (including a 48,000‑share purchase at $4.66), boosting her disclosed stake to roughly 282,000 shares — a ~20% increase that signals strong insider confidence.
- Myriad reported a quarterly beat (EPS $0.04 vs. consensus −$0.02 and revenue $209.8M vs. $207.6M) but issued Q1 guidance of $200–$203M (slightly below consensus) and left EPS guidance unspecified, creating near‑term uncertainty despite a consensus analyst rating of Hold and a $9.17 price target.
Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) Director S. Louise Phanstiel acquired 6,100 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $4.74 per share, with a total value of $28,914.00. Following the completion of the purchase, the director directly owned 183,544 shares of the company's stock, valued at approximately $869,998.56. This represents a 3.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
S. Louise Phanstiel also recently made the following trade(s):
- On Friday, February 27th, S. Louise Phanstiel bought 48,000 shares of Myriad Genetics stock. The stock was purchased at an average cost of $4.66 per share, for a total transaction of $223,680.00.
- On Thursday, February 26th, S. Louise Phanstiel purchased 50,407 shares of Myriad Genetics stock. The shares were purchased at an average cost of $4.80 per share, with a total value of $241,953.60.
Myriad Genetics Price Performance
NASDAQ:MYGN opened at $4.61 on Friday. The firm has a market cap of $431.08 million, a PE ratio of -1.17 and a beta of 1.90. The company's 50-day moving average price is $5.61 and its two-hundred day moving average price is $6.59. The company has a quick ratio of 2.12, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. Myriad Genetics, Inc. has a 12 month low of $3.76 and a 12 month high of $11.44.
Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.06. The company had revenue of $209.80 million during the quarter, compared to analysts' expectations of $207.57 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. Myriad Genetics's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 earnings per share. On average, equities analysts anticipate that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.
Hedge Funds Weigh In On Myriad Genetics
Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Myriad Genetics by 4.3% during the 4th quarter. Vanguard Group Inc. now owns 8,225,371 shares of the company's stock worth $50,586,000 after acquiring an additional 342,856 shares during the period. Millennium Management LLC boosted its position in shares of Myriad Genetics by 41.1% in the 4th quarter. Millennium Management LLC now owns 6,700,158 shares of the company's stock worth $41,206,000 after purchasing an additional 1,951,831 shares during the last quarter. State Street Corp grew its stake in shares of Myriad Genetics by 19.9% during the fourth quarter. State Street Corp now owns 5,966,567 shares of the company's stock worth $36,694,000 after purchasing an additional 990,075 shares during the period. Glenview Capital Management LLC increased its holdings in Myriad Genetics by 17.6% in the second quarter. Glenview Capital Management LLC now owns 4,587,407 shares of the company's stock valued at $24,359,000 after purchasing an additional 687,857 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Myriad Genetics by 157.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company's stock valued at $17,662,000 after purchasing an additional 1,492,405 shares during the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.
Key Myriad Genetics News
Here are the key news stories impacting Myriad Genetics this week:
- Positive Sentiment: Director S. Louise Phanstiel completed multiple open-market buys totaling ~104,507 shares across Feb. 25–27 (average prices ~$4.74–$4.80), increasing her stake ~20–27% in disclosed filings — a strong insider-confidence signal that can attract investor interest. SEC Form 4 filing
- Positive Sentiment: Zacks Research upgraded MYGN from "strong sell" to "hold," removing a severe negative rating and potentially reducing selling pressure from some model-driven funds or algorithmic screens. Zacks.com
- Neutral Sentiment: Media coverage amplified the insider activity (TipRanks coverage), which can increase short-term trading volume and retail interest but does not change fundamentals by itself. TipRanks article
- Negative Sentiment: Management updated Q1 FY2026 guidance with revenue of $200.0M–$203.0M (consensus ~$203.5M) and left EPS guidance unspecified — revenue guidance is slightly below consensus and the missing EPS figure creates uncertainty ahead of the quarter, which can pressure the stock if investors focus on short-term top-line weakness. (Company guidance release)
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. UBS Group lowered their target price on Myriad Genetics from $8.00 to $6.00 and set a "neutral" rating for the company in a research note on Tuesday. Wells Fargo & Company lowered their price objective on shares of Myriad Genetics from $6.50 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Myriad Genetics in a research report on Monday, December 29th. Piper Sandler decreased their price target on shares of Myriad Genetics from $9.00 to $8.50 and set an "overweight" rating on the stock in a research note on Tuesday, November 11th. Finally, TD Cowen restated a "hold" rating on shares of Myriad Genetics in a research report on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Myriad Genetics presently has a consensus rating of "Hold" and an average target price of $9.17.
Check Out Our Latest Analysis on Myriad Genetics
Myriad Genetics Company Profile
(
Get Free Report)
Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual's risk for various hereditary conditions and to guide personalized treatment decisions. The company's core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women's health, neurology and pharmacogenomics to support more informed clinical decision-making.
Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
